Let’s take a look at AEterna Zentaris, Inc. AEZS is an oncology drug development company that is currently working on a NDA for their leading Phase 3 product, Solorel, which is an oral diagnostic test to catch Adult Growth Hormone Deficiency. The NDA should be completed sometime this year. They are also using the Investor Relations Group (IRG) to update investors on the progress of AEterna’s products through multimedia initiatives and social networking.

Today, the share price hit $1.68, with a 52-week high of $2.19. However, this was a $3-$4 stock 3 years ago and even hit $8 back in 2004. If this NDA for Adult Growth Hormone Deficiency passes, I can’t see why this price doesn’t eventually get back up to the $4 mark and maybe even higher. They are backed by Wellington Management, their top institutional investor and a sound asset management company. The share price has gone up over 36% in the past 3 months, so I would look to scoop some shares and hold for the long run. I’m currently not invested in this company myself, but if I see a drop back into the low $1.50 range, I may reconsider.

Keeping this one on the radar. Stay tuned…….